Conditions: Migraine
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 1703
Healthy volunteers: no

Brief summary:
The purpose of this study is to investigate the efficacy and safety of MK0974 compared to a placebo for acute migraine.

Detailed description:

Arms:
arm 1: MK0974 50 mg; one orally-administered dose, plus an optional second dose (MK0974 50 mg) to treat a single moderate-to-severe migraine attack arm 2: MK0974 150 mg; one orally-administered dose, plus an optional second dose (MK0974 150 mg) to treat a single moderate-to-severe migraine attack arm 3: MK0974 300 mg; one orally-administered dose, plus an optional second dose (MK0974 300 mg or placebo) to treat a single moderate-to-severe migraine attack arm 4: Placebo; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine attack

Interventions: intervention 1: MK0974 50 mg intervention 2: MK0974 150 mg intervention 3: MK0974 300 mg intervention 4: Comparator: Placebo
Intervention descriptions: intervention 1: None intervention 2: None intervention 3: None intervention 4: MK0974 50 mg soft gel capsule Placebo; MK0974 150 mg soft gel capsule Placebo; MK0974 300 mg soft gel capsule Placebo.

Protocol document: